What Researchers Did
The researchers treated patients who had advanced mouth cancer that could not be removed by surgery with a drug called misonidazole plus radiation given inside a hyperbaric oxygen chamber, then began a larger trial to compare this approach with standard radiation in air.
What They Found
In an interim report of a pilot study followed by an ongoing randomized trial, 31 patients with advanced inoperable squamous carcinoma of the mouth received misonidazole with six 6.0 Gy radiation doses in hyperbaric oxygen at 3 ATA, and 48% were free of disease at one year and 26% at two years. The ongoing trial compares this regimen with 63.0 Gy in 30 fractions over 38 days in air. So far 114 patients have been entered, and 91 could be analyzed at six months or more. The preliminary results at 6 and 12 months favor the combination of sensitizers, and the authors report no added toxicity. The abstract gives no statistical test for this comparison.
What This Means for Canadian Patients
This report covers advanced mouth cancer that could not be treated with surgery. The abstract describes the combination of misonidazole, radiation and hyperbaric oxygen at 3 ATA as being tested and gives early results only. It does not report final results, so it cannot show whether this treatment works better than standard radiation. Patients should discuss any treatment options with their cancer care team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is an interim report: the pilot study had no comparison group, the randomized trial results are preliminary and given without numbers or a statistical test, and only 91 of the 114 patients could be analyzed at six months or more.